aleniglipron — Initial data
Q4 2026
We anticipate data from the SWITCH trial in the fourth quarter of 2026.Source filing
GPCR biotech catalysts & pipeline
STRUCTURE THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
aleniglipron — Clinical data readout
Q4 2026
· Phase 2 Body Composition clinical trial (NCT07169942): Results from a 44-week study evaluating aleniglipron's effects on body fat and overall body composition.Source filing
aleniglipron — Clinical data readout
Q4 2026
· Phase 2 T2DM clinical trial (NCT07400588): Results in adults living with T2DM and obesity or overweight.Source filing
ACCG-2671 — Topline data
1H 2027
First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027Source filing
aleniglipron — Topline data
H2 2028
We expect topline data in the second half of 2028.Source filing